PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

por Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Publicado 2021

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

por Patel, Hima, Mishra, Rosalin, Yacoub, Nour, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Publicado 2021

HER3 Alterations in Cancer and Potential Clinical Implications

por Kilroy, Mary Kate, Park, SoYoung, Feroz, Wasim, Patel, Hima, Mishra, Rosalin, Alanazi, Samar, Garrett, Joan T.
Publicado 2022

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

por Alanazi, Samar M., Feroz, Wasim, Mishra, Rosalin, Kilroy, Mary Kate, Patel, Hima, Yuan, Long, Storr, Sarah J., Garrett, Joan T.
Publicado 2023